Evidence map›Paper›PMID 23202921›Full record

ReviewInternational journal of molecular sciences2012

Crossing paths in Human Renal Cell Carcinoma (hRCC).

Guadalupe Aparicio Gallego, Vanessa Medina Villaamil, Enrique Grande, Isabel Santamarina Caínzos, Luís M Antón Aparicio

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guadalupe Aparicio GallegoBiomedical Research Institute (INIBIC), CHU A Coruña, Xubias de Abaixo s/n, PC 15006, A Coruña, Spain. vanessa.medina.villaamil@sergas.es.
Vanessa Medina Villaamil
Enrique Grande
Isabel Santamarina Caínzos
Luís M Antón Aparicio

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, cell-signaling pathways have been studied as the compilation of isolated elements into a unique cascade that transmits extracellular stimuli to the tumor cell nucleus. Today, growing evidence supports the fact that intracellular drivers of tumor progression do not flow in a single linear pathway, but disseminate into multiple intracellular pathways. An improved understanding of the complexity of cancer depends on the elucidation of the underlying regulatory networks at the cellular and intercellular levels and in their temporal dimension. The high complexity of the intracellular cascades causes the complete inhibition of the growth of one tumor cell to be very unlikely, except in cases in which the so-called “oncogene addiction” is known to be a clear trigger for tumor catastrophe, such as in the case of gastrointestinal stromal tumors or chronic myeloid leukemia. In other words, the separation and isolation of the driver from the passengers is required to improve accuracy in cancer treatment. This review will summarize the signaling pathway crossroads that govern renal cell carcinoma proliferation and the emerging understanding of how these pathways facilitate tumor escape. We outline the available evidence supporting the putative links between different signaling pathways and how they may influence tumor proliferation, differentiation, apoptosis, angiogenesis, metabolism and invasiveness. The conclusion is that tumor cells may generate their own crossroads/crosstalk among signaling pathways, thereby reducing their dependence on stimulation of their physiologic pathways.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellErbB ReceptorsHumansHypoxia-Inducible Factor 1Kidney NeoplasmsReceptors, NotchSignal TransductionTumor Suppressor Protein p53Vascular Endothelial Growth Factor ABiomarkers, TumorErbB ReceptorsHypoxia-Inducible Factor 1Receptors, NotchTumor Suppressor Protein p53Vascular Endothelial Growth Factor A

Identifiers

PMID23202921
PMCPMC3497295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.